A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.
Also called NCT07843862
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Registry
-
NCT07843862
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07843862. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HRS-4729 Injection
- Intervention (Drug)
- Mazdutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07843862- Content hash
8ebb34abe59364f0b721f261920d3e3cf7283263956926ea02330336c8c35d45